Thus, further elucidation of the molecular mechanisms governing PLA2G16 in tumor initiation and progression, alongside a comprehensive understanding of its involvement in tumor cell proliferation, holds promising potential for its application as a novel tumor biomarker and therapeutic target in clinical settings, including pancreatic cancer. This evidence concerns the gene PLAAT3 and neoplasm.